Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
15 May 2018
OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
The current system of a single price per medicine means that, for multi-indication medicines, the relationship between price and “value” can vary substantially. In this OHE…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally…
Is There Societal Support for an End of Life Premium?
8 May 2017
OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on…
Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.
Eliciting the Relative Value of Life Extension at the End of Life
29 November 2016
Rachel Baker of Glasgow Caledonian University and Koonal Shah of OHE discussed societal viewpoints regarding end of life treatments at a recent seminar.
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.
New Publication: Headroom Approach to Device Development
23 February 2016
OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.